HMNC Brain Health and Develco Pharma Announce Promising Preliminary Results in Treatment-Resistant Depression (TRD), suggesting antidepressant efficacy and showing Placebo-Level Dissociative Side Effects in Phase 2 oral prolonged-release Ketamine (KET01) Study
- Phase 2 Proof-of-Concept study in TRD patients resistant to standard antidepressants suggests positive trend in efficacy.
- Potential first-in-class oral prolonged-release formulation of ketamine, KET01, suggests larger improvement in Montgomery-Åsberg Depression Rating Scale (MADRS) scores at 15 days compared to placebo.
- Improvement in MADRS scores shown at 7 days suggestive of rapid onset of efficacy.
- Safety: no treatment-related serious adverse events with only placebo-level dissociative side-effects reported.
MUNICH, Germany, March 31, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC'' or the “Company”), a global clinical stage biopharmaceutical company pioneering the development of personalized therapies in psychiatry, together with Develco Pharma, a company specializing in the development and manufacture of orally administered modified, prolonged & chrono release drugs, today announced promising top-line results from the Phase 2 Proof-of-Concept investigator-initiated trial of its oral prolonged-release formulation of ketamine (KET01) in Treatment-Resistant Depression (TRD).
The trial suggests a positive trend in efficacy, based on the primary endpoint clinical data: After 15 days, the highest dose of 240 mg/day KET01 was associated with a larger improvement on the Montgomery-Åsberg Depression Rating Scale (MADRS) compared with placebo (Δ=-4.99, p=0.1499). In addition, KET01 appears to be a safe and well-tolerated antidepressant, with substantially limited dissociative side effects, and scores on the Clinician-Administered Dissociative States Scale (CADSS) similar to those for placebo.
The Phase 2 trial evaluated whether KET01 administered in doses of 240 mg/day and 160 mg/day for 15 days to patients with TRD as an adjunct treatment to standard antidepressants can improve depressive symptoms compared to placebo. Recruitment stopped early after inclusion of 27 patients with TRD instead of 99, due to the effects of COVID-19 together with very stringent criteria for definition of treatment resistant depression on recruitment.
The primary endpoint, change in MADRS from baseline to day 15, showed a mean advantage of -4.99 units compared with placebo (95% confidence interval (CI): -11.81, 1.83, p=0.1499) suggesting a positive trend in efficacy for the highest tested dose (240 mg/day) on the established MADRS rating scale for depressive severity.
Additionally, the data suggest KET01 has a rapid onset of action, with a clinically meaningful improvement of -5.67 units (95%CI: -12.57, 1.23, p=0.1062) already after 7 days compared with placebo.
Importantly, safety results from the trial demonstrated that KET01 was well tolerated, with no treatment-related serious adverse events reported. The scores on the Clinician-Administered Dissociative States Scale (CADSS) were similar to those for placebo.
Dr. Hans Eriksson, HMNC Brain Health’s Chief Clinical Development Officer, said, “The encouraging preliminary results we have seen demonstrate the safety of KET01, showing the potential for development of a first-in-class, oral prolonged-release formulation of ketamine treatment for patients suffering from Treatment-Resistant Depression. In addition, our data suggest that KET01 is rapidly acting with a clinically meaningful improvement compared with placebo already after 7 days, which stands in sharp contrast to standard antidepressants which have a delayed onset of action of up to several weeks.”
The study was funded by the Ketabon program, which is a joint venture between HMNC Brain Health and Develco Pharma, sponsored by University of Zurich and conducted under the central leadership of Professor Erich Seifritz, Director of the Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric University Hospital Zurich. Dr. Michael Colla coordinated the medical implementation as head of the clinical trial at the University of Zurich, as successor of Prof. Annette Brühl, after she moved to the University of Basel. The statistical evaluation of the study was carried out by SCOPE, a globally renowned CRO.
Professor Seifritz commented, “We are pleased with the top-level results from this Phase 2 study on Treatment-Resistant Depression with KET01, as they hold significant positive implications for the clinical development of oral prolonged-release ketamine to help those afflicted, making up as many as 30 percent of depression patients. Not only does the data suggest this to be a potentially safer treatment for people suffering from Major Depressive Disorder who have not found currently available antidepressants effective, but it could potentially be expanded to include additional mental-health indications in the future. Ketabon and the University of Zurich will continue to work together in the development of KET01, with future studies being planned."
HMNC Brain Health, in partnership with Develco Pharma, is about to start a multinational, larger CRO-led Phase 2 randomized, double-blind, placebo-controlled trial in patients with TRD in the second quarter of 2022. First results are expected for mid-2023.
“We are highly encouraged by the findings in this study, showing a clinically meaningful improvement and excellent tolerability in patients treated with 240 mg/day KET01. We will bring our experiences from this study to further trials with KET01 and are looking forward to the next steps in the development of this promising medication,” said Develco Pharma CEO Dr. Martin Renner.
Dr. Eriksson added, “The suggested clinically relevant improvement in efficacy and the good safety and tolerability profile that we saw in the Phase 2 Proof-of-Concept trial support our plans for the larger study which we are preparing to launch. With the capabilities of our team and strong Scientific Advisory Board, we are well placed to undertake the next steps for progressing Ketabon towards more studies and the pathway to approval and commercialization.”
About HMNC Brain Health
HMNC Brain Health (HMNC Holding GmbH) is a global precision psychiatry biopharma company pioneering the development of personalized therapies powered by predictive companion diagnostics, leading to far shorter treatments and higher remission rates. The Company develops a unique pipeline for targeting both Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD). The Company has operations both in the U.S. and Germany and is backed by a renowned global VC, several family offices, and a strategic healthcare investor. The Company now enters the next stage of its development with a large-scale licensing and fundraising agenda.
About Develco Pharma
With headquarters in Pratteln / Switzerland, Develco Pharma is a Swiss-German pharmaceutical company specializing in the development and manufacture of orally administered modified, prolonged & chrono release drugs containing known active ingredients. Established in 2006, today the company has a workforce of 130 employees. In Germany, a state-of-the-art production facility for analgesics & other indications has been in operation in Schopfheim, in the Baden region, since 2016. Develco identifies and defines pharmaceutical products containing known active ingredients and develops generic, hybrid, value added and innovative formulations backed by clinical data for the delayed or modified release of active ingredients. On the strength of its experience and innovativeness, the company has emerged as an internationally recognized provider of pharmaceuticals for the treatment of several disease areas. The customer base of Develco Pharma includes global pharmaceuticals groups. The company has some 180 market approvals in all (products of different dosages) in Europe, the U.S., Middle-East, South Africa, Asia and Australia.
About the Ketabon Program
The Ketabon program, a joint venture between HMNC Brain Health and Develco Pharma in Switzerland comprises an oral prolonged-release formulation of ketamine for TRD with minimal dissociative side effects. The pharmacokinetic profile of the prolonged-release formulation could significantly improve the risk profile and patient convenience, by minimizing dissociative side effects compared to the currently applied intravenous and intranasal ketamine therapies. TRD patients with insufficient response to standard antidepressants represent 30% of an overall estimated number of 320 million patients worldwide suffering from major depressive disorder. In this group, prolonged-release ketamine has shown high response rates. Clinical development of oral prolonged-release ketamine could also be potentially expanded into other indications, such as anxiety, aggression, PTSD, and panic disorder.
About the Psychiatric University Hospital Zurich
The Department of Psychiatry, Psychotherapy and Psychosomatics at the Psychiatric University Hospital Zurich is an internationally leading institute of translational research into innovative and novel biological and psychological treatments of psychiatric conditions, with a focus on Major Depression, Schizophrenia and Addiction. The translational approach is based on a comprehensive bio-psycho-social disease model overarching the full spectrum from molecular neuroscience to clinical and social psychiatry and back.
Alexander Schmidt, (Europe) +49 151 22 99 39 765
Anne Donohoe, (U.S.) +1212.896.1265
Investor Contacts (U.S.):
Tim Regan / Sophia Bashford
email@example.com / firstname.lastname@example.org
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
GOGL - Mandatory notification of trade by primary insiders19.5.2022 22:30:00 CEST | Press release
Eligible option holders in Golden Ocean Group Ltd (the “Company”) have today exercised share options in accordance with the terms previously announced. Ulrik Uhrenfeldt Andersen, CEO, has exercised 300,000 share options and subsequently sold 300,000 shares. Following the exercise, Mr. Andersen holds 250,000 share options. Peder Simonsen, CFO, has exercised 75,000 share options and has subsequently sold 75,000 shares. Following the exercise, Mr. Simonsen holds 200,000 share options and 500 shares. Please see the attached forms for notification and public disclosure of transaction attached for details. This notification has been publicly disclosed in accordance with Article 19 of the Market Abuse Regulation section 5-12 of the Norwegian Securities Trading Act. Attachment GOGL - Disclosure of transaction by PDMR
Brunel AGM 202219.5.2022 18:30:00 CEST | Press release
Amsterdam, 19 May 2022 – Brunel International N.V. (Brunel; BRNL), a global provider of flexible workforce solutions and expertise, today announced the voting results of the Annual General Meeting of Shareholders (AGM) of 19 May 2022. The AGM approved all voting items that were on the agenda. The shareholders adopted the financial statements for the 2021 financial year and approved the proposal to distribute a dividend of € 0.45 per share for the 2021 financial year. The dividend, less 15% dividend withholding tax, will be made payable as of 15 June 2022 at ABN AMRO Bank N.V. in Amsterdam. The shares will be quoted ex-dividend on the stock exchange of Euronext Amsterdam as of 23 May 2022. The record date is 24 May 2022 after closing of the stock exchange. Peter de Laat is reappointed as a member of the board of directors for a new term of four years. At the close of the meeting Mr Jan Arie van Barneveld, retired from the supervisory board after having served on the supervisory board fo
Scandinavian Tobacco Group A/S: Share buy-back programme increased to up to DKK 1,000 million19.5.2022 18:15:00 CEST | Press release
Company Announcement No. 35/2022 Copenhagen, 19 May 2022 Share buy-back programme increased to up to DKK 1,000 million The Board of Directors of Scandinavian Tobacco Group A/S has decided to increase the DKK 700 million share buy-back programme that was initiated 10 March 2022 (see company announcement 16/2022) by DKK 300 million. Consequently, the on-going share buy-back programme now has a value of up to DKK 1,000 million. As of 19 May 2022, Scandinavian Tobacco Group had purchased shares of a total value of DKK 128 million under the programme. Prior to the expansion of the share buy-back programme, Scandinavian Tobacco Group A/S holds a total of 1,338,431 treasury shares, corresponding to 1.44% of the total share capital. The purpose of the share buy-back programme remains to adjust the Group’s capital structure and meet obligations relating to the Group’s share-based incentive programme. The Board of Directors intends to propose to the annual general meeting in 2023 that the shares
Scandinavian Tobacco Group A/S reports Q1 results, maintains guidance for 2022 and presents revised Sustainability Strategy19.5.2022 18:15:00 CEST | Press release
Company Announcement No. 34/2022 Copenhagen, 19 May 2022 Interim report, 1 January - 31 March 2022 Scandinavian Tobacco Group A/S reports Q1 results, maintains guidance for 2022 and presents revised Sustainability Strategy For the first quarter of 2022 Scandinavian Tobacco Group delivered 2% negative organic net sales growth and 3% negative organic EBITDA growth in line with the previously communicated expectations for the quarter. The guidance for the full year of an organic EBITDA growth in the range of 0-6% is maintained. The uncertainty related to key assumptions like consumer behaviour, cost inflation and supply-chain stability remains high. The current share buy-back programme is increased by DKK 300 million to reach up to DKK 1,000 million reflecting the strong financial position of Scandinavian Tobacco Group. Consumer demand for handmade cigars in the US remained robust in the quarter though with signs at the end of the quarter of a return to the structural declining volume tre
KBC Group: Publication of transparency notification(s) received by KBC Group NV19.5.2022 18:00:00 CEST | Press release
Press release Outside trading hours – Regulated information* Brussels, 19 May 2022, 18h00 Publication of transparency notification(s) received by KBC Group NV (art. 14, 1st section of the Act of 2 May 2007 concerning the disclosure of significant participations) Summary of the notification(s) KBC Group NV has received a transparency notification on 18 May 2022, which states that FMR LLC holds 3.32% of voting rights in KBC Group, based on’ voting securities’ and ‘financial instruments that are treated as equivalent to voting securities’ combined (compared to 3.01% in the previous notification dd. 6 September 2018). That is the sum of 2.72% for voting securities (compared to 3.01% in the previous notification) and 0.60% for financial instruments that are treated as equivalent to voting securities (compared to 0% in the previous notification). Content of the notification(s) The notification(s) contain(s) following information: Reason for the notification(s): acquisition or disposal of vot